Clinical Trial Update: Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AZD7503 for HSD17B13 mRNA knockdown with pharmacokinetics, safety, and tolerability data in non-alcoholic fatty liver disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• AZD7503

Snippet

Sponsor: AstraZeneca | Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic | Phase 1 | Status: COMPLETED